Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors.

Muhammad Anees¹, Patrick L Wagner¹, Ashten Omstead¹, Erin Grayhack¹, Christopher Sherry¹, Lee D McDaniel², Matthew G Varga², Seyed Mohammad Hossein Hosseiny³, William Laframboise¹, John Nakayama¹, Thomas Krivak¹, Benny Weksler¹, Neda Dadgar¹, Shurjeel Uddin Qazi¹, Nathan Bahary¹, David L Bartlett¹, David S Tsao², Ali H Zaidi¹

¹Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA.

²BillionToOne, Menlo Park, CA, USA.

³Highmark Health, Pittsburgh, PA, USA.

PubMed PMC DOI PDF

Abstract

Timely identification of treatment failure during immune checkpoint blockade remains a critical unmet need in oncology. We evaluated a tissue-free, methylation-based circulating tumor DNA (ctDNA) assay applied serially across 142 patients with advanced solid tumors receiving immune checkpoint inhibitor monotherapy or chemo-immunotherapy in two independent prospective cohorts. Blood was collected p…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.